Qizaobaoxin Decoction ameliorates doxorubicin/trastuzumab-induced cardiotoxicity by modulating gut microbiota and associated metabolites

Abstract

Sequential treatment with anthracyclines and trastuzumab is highly effective for HER-2 positive breast cancer but poses a significant risk of cardiotoxicity. Qizaobaoxin Decoction (QZBXD), a modified Chinese herbal formula, has shown promise in protecting against antineoplastic drug-induced cardiotoxicity. This study aimed to investigate the chemical composition, efficacy, and mechanisms of QZBXD in mitigating doxorubicin/trastuzumab (DOX/TRZ)-induced cardiotoxicity. Using UPLC-Q-TOF-MS/MS, 83 compounds in QZBXD were identified, including flavonoids, organic acids, and phthalides. In DOX/TRZ-induced cardiotoxicity model, QZBXD treatment improved cardiac function (increased left ventricular ejection fraction and left ventricular fractional shortening), reduced biomarkers of myocardial injury (cTnI, BNP, LDH, CK-MB, α-HBDH), and alleviated histopathological damage. Mechanistically, 16S rDNA sequencing revealed that QZBXD restored gut microbiota diversity, reducing harmful bacteria (Ruminococcus, Oscillibacter) and increasing beneficial bacteria (Bacteroides). Untargeted metabolomics showed that QZBXD modulated tryptophan and arachidonic acid metabolism, affecting key metabolites (e.g., decreasing tryptamine and 8,9-epoxyeicosatrienoic acid, and increasing 4-hydroxy-L-tryptophan and L-formylkynurenine). Integrated analysis revealed that QZBXD confers cardioprotective effects against DOX/TRZ-induced cardiotoxicity by modulating gut microbiota composition, which subsequently influences tryptophan and arachidonic acid metabolism. This study provides a pharmacological basis for the clinical application of QZBXD in mitigating DOX/TRZ-induced cardiotoxicity.

Keywords

cardiotoxicity / doxorubicin / trastuzumab / Qizaobaoxin Decoction / multi-omics

References

[1] Bray F , Laversanne M , Sung H , Ferlay J , Siegel RL , Soerjomataram I , Jemal A . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74(3): 229–263

[2] Demissei BG , Finkelman BS , Hubbard RA , Smith AM , Narayan HK , Narayan V , Shah P , Waxman AJ , Domchek SM , Ky B . Cardiovascular function phenotypes in response to cardiotoxic breast cancer therapy. J Am Coll Cardiol 2019; 73(2): 248–249

[3] Zamorano JL , Lancellotti P , Rodriguez Muñoz D , Aboyans V , Asteggiano R , Galderisi M , Habib G , Lenihan DJ , Lip GYH , Lyon AR , Lopez Fernandez T , Mohty D , Piepoli MF , Tamargo J , Torbicki A , Suter TM; ESC Scientific Document Group . 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016; 37(36): 2768–2801

[4] Cameron D , Piccart-Gebhart MJ , Gelber RD , Procter M , Goldhirsch A , de Azambuja E , Castro G Jr , Untch M , Smith I , Gianni L , Baselga J , Al-Sakaff N , Lauer S , McFadden E , Leyland-Jones B , Bell R , Dowsett M , Jackisch C; Herceptin Adjuvant (HERA) Trial Study Team . 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 2017; 389(10075): 1195–1205

[5] Piccart M , Procter M , Fumagalli D , de Azambuja E , Clark E , Ewer MS , Restuccia E , Jerusalem G , Dent S , Reaby L , Bonnefoi H , Krop I , Liu TW , Pieńkowski T , Toi M , Wilcken N , Andersson M , Im YH , Tseng LM , Lueck HJ , Colleoni M , Monturus E , Sicoe M , Guillaume S , Bines J , Gelber RD , Viale G , Thomssen C; APHINITY Steering Committee . Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years’ follow-up. J Clin Oncol 2021; 39(13): 1448–1457

[6] Yang H , Bhoo-Pathy N , Brand JS , Hedayati E , Grassmann F , Zeng E , Bergh J , Bian W , Ludvigsson JF , Hall P , Czene K . Risk of heart disease following treatment for breast cancer—results from a population-based cohort study. eLife 2022; 11: e71562

[7] Lin M , Xiong W , Wang S , Li Y , Hou C , Li C , Li G . The research progress of trastuzumab-induced cardiotoxicity in HER-2-positive breast cancer treatment. Front Cardiovasc Med 2022; 8: 821663

[8] Curigliano G , Cardinale D , Dent S , Criscitiello C , Aseyev O , Lenihan D , Cipolla CM . Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin 2016; 66(4): 309–325

[9] Tai XH , Zhang LF , Dang CY , Zhang XX , Xue L , Liu L , Li HL . Advances in the prevention and treatment of cardiotoxicity caused by anti-tumor drugs. Chin Clin Oncol (Lin Chuang Zhong Liu Xue Za Zhi) 2023; 28(1): 70–76

[10] Li M , Han B , Zhao H , Xu C , Xu D , Sieniawska E , Lin X , Kai G . Biological active ingredients of Astragali Radix and its mechanisms in treating cardiovascular and cerebrovascular diseases. Phytomedicine 2022; 98: 153918

[11] Xu Z , Zhou H , Zhang Y , Cheng Z , Wan M , Qin W , Li P , Feng J , Shao S , Xue W , Guo H , Liu B . Recent pharmacological advances in the treatment of cardiovascular events with Astragaloside IV. Biomed Pharmacother 2023; 168: 115752

[12] Su HF , Shaker S , Kuang Y , Zhang M , Ye M , Qiao X . Phytochemistry and cardiovascular protective effects of Huang-Qi (Astragali Radix). Med Res Rev 2021; 41(4): 1999–2038

[13] Orgah JO , He S , Wang Y , Jiang M , Wang Y , Orgah EA , Duan Y , Zhao B , Zhang B , Han J , Zhu Y . Pharmacological potential of the combination of Salvia miltiorrhiza (Danshen) and Carthamus tinctorius (Honghua) for diabetes mellitus and its cardiovascular complications. Pharmacol Res 2020; 153: 104654

[14] Geng ZH , Huang L , Song MB , Song YM . Cardiovascular effects in vitro of a polysaccharide from Salvia miltiorrhiza. Carbohydr Polym 2015; 121: 241–247

[15] Milano G , Biemmi V , Lazzarini E , Balbi C , Ciullo A , Bolis S , Ameri P , Di Silvestre D , Mauri P , Barile L , Vassalli G . Intravenous administration of cardiac progenitor cell-derived exosomes protects against doxorubicin/trastuzumab-induced cardiac toxicity. Cardiovasc Res 2020; 116(2): 383–392

[16] Cho DH , Lim IR , Kim JH , Kim MN , Kim YH , Park KH , Park SM , Shim WJ . Protective effects of statin and angiotensin receptor blocker in a rat model of doxorubicin- and trastuzumab-induced cardiomyopathy. J Am Soc Echocardiogr 2020; 33(10): 1253–1263

[17] Su D , Li HY , Yan HR , Liu PF , Zhang L , Cheng JH . Astragalus improved cardiac function of adriamycin-injured rat hearts by upregulation of SERCA2a expression. Am J Chin Med 2009; 37(3): 519–529

[18] Cao Y , Shen T , Huang X , Lin Y , Chen B , Pang J , Li G , Wang Q , Zohrabian S , Duan C , Ruan Y , Man Y , Wang S , Li J . Astragalus polysaccharide restores autophagic flux and improves cardiomyocyte function in doxorubicin-induced cardiotoxicity. Oncotarget 2017; 8(3): 4837–4848

[19] Lin J , Fang L , Li H , Li Z , Lyu L , Wang H , Xiao J . Astragaloside IV alleviates doxorubicin induced cardiomyopathy by inhibiting NADPH oxidase derived oxidative stress. Eur J Pharmacol 2019; 859: 172490

[20] Zhao P , Wang Y , Zeng S , Lu J , Jiang TM , Li YM . Protective effect of astragaloside IV on lipopolysaccharide-induced cardiac dysfunction via downregulation of inflammatory signaling in mice. Immunopharmacol Immunotoxicol 2015; 37(5): 428–433

[21] Wei Y , Wu Y , Feng K , Zhao Y , Tao R , Xu H , Tang Y . Astragaloside IV inhibits cardiac fibrosis via miR-135a-TRPM7-TGF-β/Smads pathway. J Ethnopharmacol 2020; 249: 112404

[22] Zhou X , Xin Q , Wang Y , Zhao Y , Chai H , Huang X , Tao X , Zhao M . Total flavonoids of astragalus plays a cardioprotective role in viral myocarditis. Acta Cardiol Sin 2016; 32(1): 81–88

[23] Chen RC , Sun GB , Ye JX , Wang J , Zhang MD , Sun XB . Salvianolic acid B attenuates doxorubicin-induced ER stress by inhibiting TRPC3 and TRPC6 mediated Ca²⁺ overload in rat cardiomyocytes. Toxicol Lett 2017; 276: 21–30

[24] Zafar H , Saier MH Jr . Gut Bacteroides species in health and disease. Gut Microbes 2021; 13(1): 1848158

[25] Jin L , Shi X , Yang J , Zhao Y , Xue L , Xu L , Cai J . Gut microbes in cardiovascular diseases and their potential therapeutic applications. Protein Cell 2021; 12(5): 346–359

[26] Huang J , Wei S , Jiang C , Xiao Z , Liu J , Peng W , Zhang B , Li W . Involvement of abnormal gut microbiota composition and function in doxorubicin-induced cardiotoxicity. Front Cell Infect Microbiol 2022; 12: 808837

[27] Fan Y , Liang L , Tang X , Zhu J , Mu L , Wang M , Huang X , Gong S , Xu J , Liu T , Zhang T . Changes in the gut microbiota structure and function in rats with doxorubicin-induced heart failure. Front Cell Infect Microbiol 2023; 13: 1135428

[28] Lin H , Meng L , Sun Z , Sun S , Huang X , Lin N , Zhang J , Lu W , Yang Q , Chi J , Guo H . Yellow wine polyphenolic compound protects against doxorubicin-induced cardiotoxicity by modulating the composition and metabolic function of the gut microbiota. Circ Heart Fail 2021; 14(10): e008220

[29] Hu S , Zhou J , Hao J , Zhong Z , Wu H , Zhang P , Yang J , Guo H , Chi J . Emodin ameliorates doxorubicin-induced cardiotoxicity by inhibiting ferroptosis through the remodeling of gut microbiota composition. Am J Physiol Cell Physiol 2024; 326(1): C161–C176

[30] Li Z , Hu E , Zheng F , Wang S , Zhang W , Luo J , Tang T , Huang Q , Wang Y . The effects of astragaloside IV on gut microbiota and serum metabolism in a mice model of intracerebral hemorrhage. Phytomedicine 2023; 121: 155086

[31] Shen Z , Cui T , Liu Y , Wu S , Han C , Li J . Astragalus membranaceus and Salvia miltiorrhiza ameliorate diabetic kidney disease via the “gut-kidney axis”. Phytomedicine 2023; 121: 155129

[32] Du XQ , Shi LP , Chen ZW , Hu JY , Zuo B , Xiong Y , Cao WF . Astragaloside IV ameliorates isoprenaline-induced cardiac fibrosis in mice via modulating gut microbiota and fecal metabolites. Front Cell Infect Microbiol 2022; 12: 836150

[33] Wang W , Xu AL , Li ZC , Li Y , Xu SF , Sang HC , Zhi F . Combination of probiotics and Salvia miltiorrhiza polysaccharide alleviates hepatic steatosis via gut microbiota modulation and insulin resistance improvement in high fat-induced NAFLD mice. Diabetes Metab J 2020; 44(2): 336–348

[34] Wang L , Wang R , Wei GY , Wang SM , Du GH . Dihydrotanshinone attenuates chemotherapy-induced intestinal mucositis and alters fecal microbiota in mice. Biomed Pharmacother 2020; 128: 110262

[35] Yoshida N , Emoto T , Yamashita T , Watanabe H , Hayashi T , Tabata T , Hoshi N , Hatano N , Ozawa G , Sasaki N , Mizoguchi T , Amin HZ , Hirota Y , Ogawa W , Yamada T , Hirata KI . Bacteroides vulgatus and Bacteroides dorei reduce gut microbial lipopolysaccharide production and inhibit atherosclerosis. Circulation 2018; 138(22): 2486–2498

[36] Zhang Y , Sun D , Zhao X , Luo Y , Yu H , Zhou Y , Gao Y , Han X , Duan Y , Fang N , Duan X , Li T , Zhang S , Gong Y , Li Y . Bacteroides fragilis prevents aging-related atrial fibrillation in rats via regulatory T cells-mediated regulation of inflammation. Pharmacol Res 2022; 177: 106141

[37] Grahnemo L , Nethander M , Coward E , Gabrielsen ME , Sree S , Billod JM , Engstrand L , Abrahamsson S , Langhammer A , Hveem K , Ohlsson C . Cross-sectional associations between the gut microbe Ruminococcus gnavus and features of the metabolic syndrome. Lancet Diabetes Endocrinol 2022; 10(7): 481–483

[38] Cui X , Ye L , Li J , Jin L , Wang W , Li S , Bao M , Wu S , Li L , Geng B , Zhou X , Zhang J , Cai J . Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients. Sci Rep 2018; 8(1): 635

[39] Zuo K , Li J , Li K , Hu C , Gao Y , Chen M , Hu R , Liu Y , Chi H , Wang H , Qin Y , Liu X , Li S , Cai J , Zhong J , Yang X . Disordered gut microbiota and alterations in metabolic patterns are associated with atrial fibrillation. Gigascience 2019; 8(6): giz058

[40] Jang C , Chen L , Rabinowitz JD . Metabolomics and isotope tracing. Cell 2018; 173(4): 822–837

[41] Razquin C , Ruiz-Canela M , Toledo E , Hernández-Alonso P , Clish CB , Guasch-Ferré M , Li J , Wittenbecher C , Dennis C , Alonso-Gómez A , Fitó M , Liang L , Corella D , Gómez-Gracia E , Estruch R , Fiol M , Lapetra J , Serra-Majem L , Ros E , Aros F , Salas-Salvadó J , Hu FB , Martínez-González MA . Metabolomics of the tryptophan-kynurenine degradation pathway and risk of atrial fibrillation and heart failure: potential modification effect of Mediterranean diet. Am J Clin Nutr 2021; 114(5): 1646–1654

[42] Ma K , Yang J , Shao Y , Li P , Guo H , Wu J , Zhu Y , Zhang H , Zhang X , Du J , Li Y . Therapeutic and prognostic significance of arachidonic acid in heart failure. Circ Res 2022; 130(7): 1056–1071

RIGHTS & PERMISSIONS

Higher Education Press